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Foreword
Publicity regarding ovarian cancer in the lay literature has resulted in widespread
recognition that ovarian cancer is now the major cancer health hazard for American
women. The failure to develop a specific screening test and the lack ofearlywarning
symptoms result in approximately 70 percent of the women with ovarian cancer
presentingwith stage III or IV disease.
It has recently been recognized that certain epidemiologic features are associated
with the development of ovarian cancer. These include first-degree relatives who
have experienced the disease, nulliparity, and a great number ofovulatory cycles. In
turn, women who have a reduced number of ovulatory cycles through childbearing,
breast-feeding, and use oforal contraceptives appear to have a reduced risk for this
cancer. In addition, Caucasians appear to have a higher incidence ofovarian cancer
than non-Caucasians. The Yale Early Detection Program for Ovarian Cancer uses
these features to recruit women at high risk for ovarian cancer to participate in an
intense program, involving physical examinations, circulating tumor markers, and
endovaginal ultrasound and color Doppler flow studies. The rationale and back-
ground for the Yale Early Detection Program and preliminary experiences of this
program are presented in the first two papers in this issue.
Once ovarian cancer has developed, taxol, an agent active in ovarian cancer, may
be employed for those who have failed at least three different treatments with prior
chemotherapy. This drug is now available through the Comprehensive Cancer
Centers. Taxol is active in women with ovarian cancer that is resistant to platinum-
based chemotherapy. A review oftaxol, its pharmacology, and its activity in ovarian
cancer management is presented by Dr. Markman.
The management ofminor degrees ofcervical dysplasia associatedwith the human
papillomavirus continues to be aproblem forgynecologists. Dr. John A. Carmichael
presents a very conservative approach to the management of these changes with
significant success in following Canadian women who do not show evidence of
progression once the degree of cervical dysplasia is confirmed by colposcopic-
directed biopsies. Dr. Carmichael's approach appears to be cost-effective in the
population that he has followed; its implication for Americans is of great signifi-
cance.
Recent developments in laparoscopic surgery have resulted in many more women
undergoing laparoscopic assessment of adnexal masses. The conservative manage-
ment ofan adnexal mass and the role oflaparoscopy and ultrasound are discussed in
the paper by Drs. Thornton and DeCherney.
Patients with a prior history of endometrial cancer are at risk for developing
recurrence of this disease, particularly if the tumors are poorly differentiated or
advanced. Manywomen with endometrial cancer havewell-differentiated adenocar-
cinoma, however, and are at extremely low risk for recurrence. The benefits of
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estrogen replacement therapy versus the risks in such patients are addressed in Drs.
Hutchinson-Williams and Gutmann's article. That there is a dearth of knowledge
regarding hormone replacement therapy in women at high risk for breast cancer is
apparent from the review by these two authors. Implications for clinical trials are
obvious from this review article.
Human chorionic gonadotropin, the glycoprotein that is used to detect early
pregnancies and monitor women with gestational trophoblastic disease, is discussed
in the article by Dr. Cole. Human chorionic gonadotropin assays have been noted, at
times, to vary from one laboratory to the next. Dr. Cole's studies explain, from a
molecular basis, why assay results mayvary and how to select the proper test for the
physician's use. Gestational trophoblastic disease, while infrequent in the United
States, is a common problem in Asia. A thorough review ofgestational trophoblastic
disease management is presented by Dr. Goldstein in the final paper of The Ninth
Annual Ella T. Grasso Memorial Conference.
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